Fig. 1: LSD1 inhibition by GSK elevates cytokine production and decreases inhibitory receptor expression in in vitro activated CD8⁺ T cells.

a Principal component analysis (PCA) of RNA-seq data of mouse CD8⁺ T cells activated and expanded in vitro for 5 days with the treatment of GSK2879552 (GSK) or vehicle control (Veh) (n = 3 mice per group). b Volcano plot showing differential gene expression in RNA-seq analysis of GSK- versus Veh-treated CD8⁺ T cells (n = 3, [Fold change] > 1.5 and q-value < 0.05 as the cutoff]). c Dot map showing the top 10 terms in the GO analysis of the upregulated genes in the comparison of GSK- versus Veh-treated CD8⁺ T cells. P-values were calculated by one-sided Fisher’s exact test and adjusted by the Benjamini-Hochberg method. d Heatmaps showing differential gene expression of effector molecules, chemokines, inhibitory receptors, and transcription factors (q < 0.05, marked in bold). Flow cytometry of cytokines (e), GzmB (f), inhibitory receptors (g), and SLAMF6 (h) expressed in GSK- or Veh-treated CD8⁺ T cells (n = 3). MFI, mean fluorescence intensity. i Flow cytometry analysis of frequencies of CD44⁺CD62L⁺ cells in GSK- or Veh-treated CD8⁺ T cells (n = 3). Data in (e–i) are presented as mean ± standard deviation (SD) and are representative of three independent experiments. Statistical significance was determined by two-sided unpaired t-test (e–i). Source data are provided as a Source Data file.